Print  |  Close

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study


Active: Yes
Cancer Type: Hematopoietic Malignancies
Solid Tumor
NCT ID: NCT03391778
Trial Phases: Phase I Protocol IDs: 208750 (primary)
NCI-2018-01288
ADP-0000-002
Eligibility: 0 Years and older, Male and Female Study Type: Other
Study Sponsor: GlaxoSmithKline
NCI Full Details: http://clinicaltrials.gov/show/NCT03391778

Summary

This trial will evaluate long term safety of participants who have received GlaxoSmithKline
(GSK) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Objectives

Participants who received a GSK adoptive cell therapy will be enrolled in this
non-therapeutic, multi-center, long term follow-up (LTFU) study and will be followed for up
to 15 years post-infusion of lentiviral vector-based adoptive cell therapy. Participants will
be monitored for safety following last adoptive cell therapy infusion.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.